Team |
David Hallal
David Hallal

David Hallal

Chairman & Chief Executive Officer, ElevateBio

David is a 30-year veteran of the biopharmaceutical industry and has expertise in early-stage company building and operating large multinational biotech companies. He is Chairman & CEO of ElevateBio and AlloVir, an ElevateBio portfolio company. 

Previously, David spent more than a decade at Alexion Pharmaceuticals as CEO, Chief Operating Officer, and Chief Commercial Officer and brought the company from the pre-commercial stage to greater than $3 billion in annual revenues. Before joining Alexion, he held commercial leadership positions at Amgen, Biogen, and Eyetech Pharmaceuticals and expanded the adoption of first-in-class products in hematology, oncology, nephrology, immunology and ophthalmology.

David is currently Chairman of the Board at both iTelos Therapeutics, an MPM Capital portfolio company, and Scholar Rock, and serves on the board at Seer. He received his BA in psychology from the University of New Hampshire.

Connect with

Visionary science, driven by visionary values.

Our Mission

To rewrite the future by curing disease, making any edit, anywhere.

Our Vision

To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.

Our Values

We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.